Patents Examined by Noble E Jarrell
  • Di-substituted pyrazole compounds for the treatment of diseases
    Patent number: 11497738
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions in treating a condition, disease, or disorder associated with abnormal activation of the SREBP pathway, including metabolic disorders such as obesity, cancer, cardiovascular disease, and nonalcoholic fatty liver disease (NAFLD) wherein the compound is according to Formula (I).
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: November 15, 2022
    Assignee: FGH BIOTECH, INC.
    Inventors: Joel Huff, Motonari Uesugi, John Kincaid
  • Compositions and methods for the treatment of fungal infections
    Patent number: 11485730
    Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX or Formula X and, the methods for the treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fungal infections.
    Type: Grant
    Filed: January 10, 2022
    Date of Patent: November 1, 2022
    Assignee: Cellix Bio Private Limited
    Inventor: Mahesh Kandula
  • Compounds and methods useful in the treatment of a PRMT5-mediated disorder
    Patent number: 11485731
    Abstract: The present disclosure relates to compounds suitable for the inhibition of protein arginine methyl-transferase (PRMT), in particular PRMT5. These compounds may be for use as therapeutic agents, in particular, agents for use in the treatment and/or prevention of proliferative diseases, such as cancer.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: November 1, 2022
    Assignee: ARGONAUT THERAPEUTICS LIMITED
    Inventors: Andrew Morley, Rebecca Miller, Nicholas La Thangue
  • Inhibitors of short-chain dehydrogenase activity for promoting neurogenesis and inhibiting nerve cell death
    Patent number: 11478458
    Abstract: A method of promoting neuroprotection in a subject from axonal degeneration, neuronal cell death, and/or glia cell damage after injury, augmenting neuronal signaling underlying learning and memory, stimulating neuronal regeneration after injury, and/or treating a disease, disorder, and/or condition of the nervous system in a subject in need thereof includes administering to the subject a therapeutically effective amount of a 15-PGDH inhibitor.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: October 25, 2022
    Assignees: CASE WESTERN RESERVE UNIVERSITY, BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, THE UNIVERSITY OF IOWA
    Inventors: Sanford Markowitz, Joseph Ready, Andrew Pieper
  • IgG-binding peptide, and specific modification of antibody with said peptide
    Patent number: 11472865
    Abstract: It is an object of the present invention to provide a method for modifying an antibody in a specific and simple manner, and others. The present invention relates to: an IgG-binding peptide, an IgG-binding peptide modified with a crosslinking agent, a complex of an IgG-binding peptide modified with the crosslinking agent and IgG, a method for producing the complex, and others.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: October 18, 2022
    Assignee: Kagoshima University
    Inventor: Yuji Ito
  • Methods and compositions relating to adjuvants
    Patent number: 11464854
    Abstract: The methods and compositions described herein relate to methods of immunization or stimulating an immune response, e.g., using agonists of TLR7 and/or TLR8 as antigens. The methods and compositions described herein have particular relevance to use in infants.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: October 11, 2022
    Assignees: Children's Medical Center Corporation, University of Montana
    Inventors: Ofer Levy, David Dowling, Helene Bazin-Lee, David Burkhart, Jay Evans, Alyson Jessica Smith
  • Carcinogenesis inhibitor
    Patent number: 11464762
    Abstract: A carcinogenesis inhibitor having no side effect and having an excellent effect by oral administration. A carcinogenesis inhibitor containing a hydantoin derivative or a pharmaceutically acceptable salt thereof as an active ingredient shows an inhibiting action for polyp formation and for cell proliferation, and has no side effect and highly safe whereby it is very highly useful as a pharmaceutical agent and a food such as supplement which prevent the occurrence and progress of cancer, inhibits the recurrence and metastasis of cancer and further achieves the therapeutic effect.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: October 11, 2022
    Assignees: NATIONAL CANCER CENTER, NIPPON ZOKI PHARMACEUTICAL CO., LTD.
    Inventors: Michihiro Mutoh, Yurie Kurokawa, Gen Fujii, Shingo Miyamoto
  • Phthalocyanine dye compounds, conjugates and methods of use thereof
    Patent number: 11466158
    Abstract: Disclosed herein are phthalocyanine dyes, and conjugates thereof, useful as fluorescent reporters for bioassays, for optical imaging and as therapeutic conjugates as the photosensitizing agents in light-based therapies including photoimmuno therapy (PIT). Certain phthalocyanine dyes disclosed herein are water soluble, and possess photophysical and photochemical profiles useful for use in imaging or therapy.
    Type: Grant
    Filed: September 22, 2021
    Date of Patent: October 11, 2022
    Assignee: RAKUTEN MEDICAL, INC.
    Inventors: Juan Betancort, Lew Makings, Torsten Wiemann
  • Di-macrocycles
    Patent number: 11453652
    Abstract: The invention relates to chemical compounds and complexes that can be used in therapeutic and diagnostic applications.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: September 27, 2022
    Assignee: LUMIPHORE, INC.
    Inventors: Darren Magda, Jide Xu, Nathaniel G. Butlin
  • Composition, photoelectric conversion element, and imaging device
    Patent number: 11447639
    Abstract: A composition contains a phthalocyanine derivative represented by the following formula: where R1 to R8 are independently an alkyl group, M is Si, each of R9 and R10 is any one of substituents represented by the following formulas, R11 to R13 are independently an alkyl group, and R14 to R18 are independently an alkyl group or an aryl group:
    Type: Grant
    Filed: September 7, 2020
    Date of Patent: September 20, 2022
    Assignee: PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD.
    Inventors: Hiroaki Iijima, Masaya Hirade, Manabu Nakata, Taniyuki Furuyama
  • Maytansinoid derivatives, conjugates thereof, and methods of use
    Patent number: 11446389
    Abstract: Provided herein are maytansinoid compounds, derivatives thereof, conjugates thereof, and methods of treating or preventing proliferative diseases with the same.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: September 20, 2022
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Thomas Nittoli, Thomas P. Markotan
  • Phospholipid ether analogs as cancer-targeting drug vehicles
    Patent number: 11439709
    Abstract: The present invention is directed to therapeutic compounds capable of targeting cancer cells and cancer stem cells. The present invention is further directed to compositions comprising these therapeutic compounds and methods of treating cancer comprising administering these therapeutic compounds.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: September 13, 2022
    Assignee: Cellectar Biosciences, Inc.
    Inventors: Jamey P. Weichert, Anatoly Pinchuk, Kevin Kozak, Marc Longino, Joseph Grudzinski, Benjamin Titz, Chorom Pak, Nathan Stehle
  • Method for improving or enhancing cognition
    Patent number: 11433057
    Abstract: Disclosed herein are a method for improving cognition in an individual having findings consistent with a cognitive impairment, and a method of enhancing cognition in an individual. The methods include administering a therapeutically effective amount of (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane or a metabolite or a pharmaceutically acceptable salt thereof to the individual.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: September 6, 2022
    Assignee: Vanda Pharmaceuticals Inc.
    Inventor: Mihael H. Polymeropoulos
  • Selective ligands for tau aggregates
    Patent number: 11434237
    Abstract: The invention provides compounds of formula (I) and compositions comprising compounds of formula (I). The invention further provides uses of the compounds of formula (I) and compositions comprising compounds of formula (I), including the use of such compounds for the detection of tau deposits, and the use of such compounds and compositions as diagnostic agents in the diagnosis or monitoring of the progression of a disease or disorder such as Alzheimer's disease or corticobasal degeneration, or for the prevention or treatment of a disease or disorder such as Alzheimer's disease or corticobasal degeneration.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: September 6, 2022
    Assignee: KARIN & STEN MORTSTEDT CBD SOLUTIONS AB
    Inventors: Peter Nilsson, Hamid Shirani
  • Pesticidally active heterocyclic derivatives with sulfur containing substituents
    Patent number: 11413291
    Abstract: Compounds of formula I (I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as pesticides and can be prepared in a manner known per se.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: August 16, 2022
    Assignee: SYNGENTA PARTICIPATIONS AG
    Inventors: Sebastian Rendler, Andrew Edmunds, Michel Muehlebach, Girish Rawal, Indira Sen, Vikas Sikervar, Daniel Emery
  • Amphiphilic and mesogenic organic dyes for tailor-made reflective low-dimensional materials
    Patent number: 11407743
    Abstract: The present invention relates to a compound of the following formula (I): The invention also relates to uses thereof as dye or pigment, notably as a luster pigment. The invention relates also to a reflective or photonic or nanophotonic or optoelectronic device comprising a compound of the invention. The invention relates also to a metal-like reflective coating, a metal-like particle or an organic-based metal-like liquid film comprising a compound of the invention.
    Type: Grant
    Filed: July 5, 2019
    Date of Patent: August 9, 2022
    Assignees: Sorbonne Universite, Centre National De La Recherche Scientifique, Universite de Paris
    Inventors: Philippe Laine, Laurélie Poulard, Grégory Dupeyre, Valerie Marvaud
  • C17, C20, and C21 substituted neuroactive steroids and their methods of use
    Patent number: 11396525
    Abstract: Described herein are neuroactive steroids or a pharmaceutically acceptable salt thereof. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. Also provided are pharmaceutical compositions comprising a compound described herein and methods of use and treatment, e.g., such as for inducing sedation and/or anesthesia.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: July 26, 2022
    Assignee: Sage Therapeutics, Inc.
    Inventors: Albert Jean Robichaud, Gabriel Martinez Botella, Boyd L. Harrison, Francesco G. Salituro, Andrew Griffin, Maria Jesus Blanco-Pillado
  • Solid state form of Valbenazine
    Patent number: 11384077
    Abstract: Salts and solid state forms of Valbenazine, including Valbenazine ditosylate, processes for preparation thereof, pharmaceutical compositions thereof, and uses thereof are disclosed.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: July 12, 2022
    Assignee: ASSIA CHEMICAL INDUSTRIES LTD.
    Inventors: Khaled Haj Ali, Marina Yarovoy, Jonathan Enav
  • Treatment of cancer by stimulation of IL-12 production
    Patent number: 11382902
    Abstract: The present invention relates to a compound and composition for use in the stimulation of IL-12 production and IFN-? production, which compound is selected from: tert-butyl N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]-3,5-difluorophenyl}ethyl)-L-alaninate, or a pharmaceutically acceptable salt, hydrate or solvate thereof; and N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]-3,5-difluorophenyl}ethyl)-L-alanine.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: July 12, 2022
    Inventors: David Festus Charles Moffat, Martin John Perry, Stephen Mark Anderton, Clare Louise Doris
  • Crystalline sodium salt of 5-methyl-(6S)-tetrahydrofolic acid
    Patent number: 11377448
    Abstract: The present invention is directed to a crystalline sodium salt of 5-methyl-(6S)-tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:1.51 to 1:2.5 and/or hydrates and/or solvates thereof, as well as, a process of obtaining the same.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: July 5, 2022
    Assignee: MERCK PATENT GMBH
    Inventors: Rudolf Moser, Viola Groehn, Fritz Blatter, Martin Szelagiewicz, Ruth Boehni Stamm, Markus Ruettimann